Written question asked by Bishop of St Albans (Bishops (affiliation)) on Wednesday, 18 October 2023, in the House of Lords. It was due for an answer on Wednesday, 1 November 2023. It was answered by Lord Markham (Conservative) on Wednesday, 25 October 2023 on behalf of the Department of Health and Social Care.
Vorasidenib
- Question
-
To ask His Majesty's Government what discussions they have had with Servier to expand access to vorasidenib for patients that might benefit by including it in the early access to medicines scheme, or by any other means.
- Answer
-
The Department has had no specific discussions with Servier regarding vorasidenib, and neither has the Medicines and Healthcare Products Regulatory Agency (MHRA). The MHRA has not issued a scientific opinion for Vorasidenib under the early access to medicines scheme but should an application for this be received, the MHRA will consider this accordingly.
Secondary information
- Type
- Written question
- Reference
- HL10663
- Session
- 2022-23
- Subjects
- Servier Laboratories Vorasidenib
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2023-10-25 13:24:26 +0100
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/lords/2022-23/HL10663
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/lords/2022-23/HL10663
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/lords/2022-23/HL10663